Last reviewed · How we verify
NCT03736473
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
Phase 1 trial testing MEDI9447 (oleclumab) in Advanced Solid Malignancies in 6 participants. Completed in 19 June 2019.
19 June 2019
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 6 |
| Start date | 7 November 2018 |
| Primary completion | 19 June 2019 |
| Estimated completion | 19 June 2019 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- MEDI9447 (oleclumab) — full drug profile →
Conditions studied
- Advanced Solid Malignancies — all drugs for Advanced Solid Malignancies →
Sponsor
AstraZeneca — full company profile →
Who can join
20 and older, any sex, with Advanced Solid Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of MEDI9447 in Japanese patients with advanced solid malignancies.This study consists of 2 cohorts. Cohort 1 (dose level 1) and Cohort 2 (dose level 2). At least 3 or up to 6 evaluable Japanese patients with advanced solid malignancies will be enrolled in each cohort.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S, Alatzoglou D, Irving M, Ménétrier-Caux C, et al · · 2019 · cited 326× · PMID 31244820 · DOI 10.3389/fimmu.2019.00925 -
CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C, Yin S, To KKW, Fu L. · · 2023 · cited 230× · PMID 36859386 · DOI 10.1186/s12943-023-01733-x -
Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches.
Thompson EA, Powell JD. · · 2021 · cited 61× · PMID 32903139 · DOI 10.1146/annurev-med-060619-023155 -
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X, Xie L. · · 2022 · cited 54× · PMID 35836249 · DOI 10.1186/s13046-022-02430-1 -
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.
Chrétien S, Zerdes I, Bergh J, Matikas A, et al · · 2019 · cited 47× · PMID 31060337 · DOI 10.3390/cancers11050628 -
Targeting Immunometabolism Mediated by CD73 Pathway in <i>EGFR</i>-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.
Passarelli A, Aieta M, Sgambato A, Gridelli C. · · 2020 · cited 37× · PMID 32760402 · DOI 10.3389/fimmu.2020.01479 -
Targeting tumor-infiltrating tregs for improved antitumor responses.
Qin D, Zhang Y, Shu P, Lei Y, et al · · 2024 · cited 36× · PMID 38500876 · DOI 10.3389/fimmu.2024.1325946 -
The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies.
Wang L, Zhang J, Zhang W, Zheng M, et al · · 2024 · cited 28× · PMID 38799637 · DOI 10.1016/j.apsb.2023.12.004
Verify or expand the search:
- PubMed search for NCT03736473
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Malignancies
Currently open trials in the same condition.
- NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
- NCT06927297 — Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors · Phase 1 · recruiting
- NCT06760481 — Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIG · Phase 1 · active not recruiting
- NCT06899061 — Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saru · Phase 1 · active not recruiting
- NCT05417594 — Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignanc · Phase 1, PHASE2 · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03736473 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 8 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03736473.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing